Fasedienol did not meet primary or secondary endpoints in the PALISADE-4 Phase 3 trial for social anxiety disorder, but a post-hoc analysis showed nominal significance in patients with very severe symptoms. Plans are underway for a new Phase 3 trial with LSAS as the primary endpoint.Original docume…
Fasedienol did not meet primary or secondary endpoints in the PALISADE-4 Phase 3 trial for social anxiety disorder, but a post-hoc analysis showed nominal significance in patients with very severe symptoms. Plans are underway for a new Phase 3 trial with LSAS as the primary endpoint.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
